Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients

Abstract

We investigated the effect of niacin (nicotinic acid prolonged release) on forearm vasodilatory function and arterial compliance in statin-treated type 2 diabetic patients with endothelial dysfunction. In a parallel group study, we randomised 15 subjects, with LDL-cholesterol ≤2.5 mmol/L, to niacin (dose titrated to 1500 mg/day over 8 weeks, then maintained for a further 12 weeks) or no additional treatment. Niacin increased maximal post-ischaemic forearm blood flow (mean ± SEM 6.4±2.4 vs. —2.3±1.2 ml/100 ml/min, p = 0.001) and small artery compliance (1.3±0.8 vs. —2.3±1.1 ml/mmHg, p = 0.01) compared with no additional treatment, but did not alter large artery compliance, blood pressure nor heart rate. Niacin decreased serum triglycerides by 47% (p = 0.04), with no change in LDL-cholesterol, HDL-cholesterol, apolipoprotein (Apo) B-100 nor ApoA-I (p > 0.05). Adding niacin to statin therapy improves small artery vasodilatory function and compliance in type 2 diabetes. This may relate to a decrease in serum triglycerides and/or a direct benefit of niacin on vascular biology.

Keywords

Arterial compliance niacin statins type 2 diabetes vasodilatory function

References

Kearney PM , Blackwell L. , Collins R. , Keech A. , Simes J. , Peto R. , et al. Efficacy of cholesterol lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-25.

Collins R. , Armitage J. , Parish S. , Sleigh P. and Peto R. MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.

Watts GF , O’Brien SF , Silvester W. and Millar JA Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci 1996; 91: 567-73.

Woodman RJ , Playford DA and Watts GF Basal production of nitric oxide (NO) and non-NO vasodilators in the forearm microcirculation in Type 2 diabetes: Associations with blood pressure and HDL cholesterol. Diabetes Res Clin Pract 2006 ; 71: 59-67.

McVeigh G. , Brennan G. , Hayes R. , Cohn J. , Finkelstein S. and Johnston D. Vascular abnormalities in non-insulin-dependent diabetes mellitus identified by arterial waveform analysis. Am J Med 1993 ; 95: 424-30.

Weinberger MH , Fineberg NS , and Fineberg SE The influence of blood pressure and carbohydrate tolerance on vascular compliance in humans . Am Journal Hypertens 2002; 15: 678-82.

Perticone F. , Ceravolo R. , Pujia A. , Ventura G. , Iacopino S. , Scozzafava A. et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.

Grey E. , Bratteli C. , Glasser SP , Alinder C. , Finkelstein SM , Lindgren BR et al. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens 2003; 16: 265-9.

Kuvin JT , Ramet ME , Patel AR , Pandian NG , Mendelsohn ME and Karas RH A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002; 144: 165-72.

10.

Warnholtz A. , Wild P. , Ostad MA , Elsner V. , Stieber F. , Schinzel R. et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: Results of the randomised, double-blind, placebo-controlled INEF study. Atherosclerosis 2009; 204: 216-21.

11.

Lee JMS , Robson MD , Yu LM , Shirodaria CC , Cunnington C. , Kylintireas I. et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009; 54: 1787-94.

12.

Taylor AJ , Villines TC , Stanek EJ , Devine PJ , Griffen L. , Miller M. et al. Extended-release niacin or ezetimibe and carotid intima-media thickness . N Engl J Med 2009; 361: 2113-22.

13.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32: S62-7.

14.

Watts GF , Herrmann S. , Dogra GK , Playford DA , Best JD , Thomas MAB et al. Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int 2001; 60: 182-9.

15.

Woodman RJ , Watts GF Measurement and application of arterial stiffness in clinical research: focus on new methodologies. Med Sci Monit 2003; 9: RA101-9.

16.

Anderson RA , Evans ML , Ellis GR , Graham J. , Morris K. , Jackson SK et al. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 2001; 154: 475-83.

17.

Teno S. , Uto Y. , Nagashima H. , Endoh Y. , Iwamoto Y. , Omori Y. et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000; 23: 1401-06.

18.

Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia . Br J Pharmacol 2009; 158: 429-41.

19.

Clinical Trial. AIM HIGH: Niacin plus statin to prevent vascular events. Available at: http://clinicaltrials.gov/ct2/show/NCT00120289?term=AIM-HIGH&rank=2 . (Accessed 20 January 2010).

20.

Clinical Trial. Treatment of HDL to reduce the incidence of vascular events. HPS2-THRIVE. Available at http://clinicaltrials.gov/ct2/show/NCT00461630?term=HPS2-THRIVE&rank=1 . (Accessed 20 January 2010).